138results about "Cis-trans-isomerases" patented technology

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of the FK 506-binding protein 7, or prolylisomerase, as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

The instant invention pertains to the discovery of two novel regulatory mechanisms of NF-kB. The instant invention demonstrates that NF-kB is regulated by Pin1-catalyzed prolyl isomerization and ubiquitin-mediated proteolysis of p65. Accordingly, the instant invention provides methods for regulating NF-kB, and diseases and disorders associated with NF-kB. Further, the invention provides compositions capable of modulating the activity or expression of NF-kB, Pin1, and/or the proteolysis of p65.

The invention relates to a modified PIN4 gene, the wild type of which is as identified in SEQ ID No. 1, encoding the protein of SEQ ID No. 5, or the wild type of which encodes a protein that has a sequence similarity of at least 80% to SEQ ID No. 5, which modified PIN4 gene encodes a protein that comprises an amino acid change as a result of the modification, and which modified protein is capable of inducing parthenocarpic fruit set when present in a plant. The invention also relates to plants and fruits that carry the gene. Such plants are capable of parthenocarpic fruit set and the fruits do not contain seeds. The invention further relates to use of the gene in breeding and producing plants capable of parthenocarpic fruit set.

A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.

The present invention relates to a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an extracellular antigen-binding domain, a transmembrane domain and a intracellular first chemical inducer of dimerization binding domain 1 (CBD1); and (ii) an intracellular signalling component comprising a signalling domain and a second chemical inducer of dimerization binding domain 2 (CBD2); wherein CBD1 and CBD2 are capable of simultaneously binding to a chemical inducer of dimerization (CID); wherein, in the absence of the CID, binding of the antigen-binding component to antigen does not result in signalling through the signalling component; whilst, in the presence of the CID, the receptor component and the signalling component heterodimerize and binding of the antigen-binding domain to antigen results in signalling through the signalling domain.

The invention relates to engineered Escherichia coli capable of high-yield production of fumaric acid; specifically, fumarase coded genes fumA and fumC of Escherichia coli are knocked off, and maleic cis-trans isomerase gene from Serratia marcescens is converted to obtain the engineered Escherichia coli. The invention also discloses a method of synthesis of catalyzing fumaric acid from maleic acid by using the engineered Escherichia coli. The method includes culturing the engineered Escherichia coli by fermenting, subjecting the engineered Escherichia coli to high-density inductive expression when OD600 reaches 40-80, and applying the obtained fermentation broth to biochemical catalysis of maleic acid in presence of Engineered Escherichia coli to obtain fumaric acid. The genes fumA and fumC in the Escherichia coli are knocked off by using Red homologous recombination, a metabolic pathway of its fumaric acid to L-malic acid is cut off, the maleic cis-trans isomerase from Serratia marcescens is then expressed, and the obtained genetically-engineered Escherichia coli can efficiently convert maleic matrix to synthesize high-purity fumaric acid, there is nearly no L-malic acid byproduct synthesized, and basis is provided for the industrialized production of fumaric acid by whole-cell process catalysis of maleic acid.

The invention discloses thermostability transformation of maleic acid cis-trans isomerase and application thereof, and belongs to the field of enzyme engineering. The maleic acid cis-trans isomerase gene maiA from serratia marcescens is subjected to thermostability transformation by a semi-rational design method. Compared with the wild maleic acid cis-trans isomerase, the obtained mutant has the advantages that the half-life period of the mutant G27A-G171A at 55 DEG C is 2.9 times of that of the wild type, and the enzyme activity is 1.96 times of that of the wild type; the half-life period of the mutant G27A-K104R is 4.18 times of the wild type at 55 DEG C, and the enzyme activity is 1.59 times of that of the wild type.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.

The invention relates to a protein mutant, particularly a maleate cis-trans isomerase, and a coding gene and application thereof. The amino acid sequence of the maleate cis-trans isomerase is disclosed as SEQ ID NO.4, or an amino acid sequence with equal functions, which is derived from SEQ ID NO.4 and subjected to substitution, deletion or addition of one or more amino acids. Compared with the wild type maleate cis-trans isomerase, the changes of the specific amino acid sequence of the mutant as follows: K51I (the 51st lysine is changed into isoleucine), R177S (the 177th arginine is changed into serine), and A212G (the 212th alanine is changed into glycine). The test verifies that the enzyme activity of the mutant is enhanced by 2.71 times as compared with the wild type maleate cis-trans isomerase.

The invention is directed to a system comprising a lentivirus vector particle which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, a Cas9 protein, and optionally a donor nucleic acid molecule comprising a second DNA sequence. The invention also is directed to a method of altering a DNA sequence in a host cell using such a system, where the host cell can be in a human and the altered DNA can be of the human β-globin gene. The invention also is directed to a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein. The invention also is directed to sequences of vectors that can be used in the system and method.